Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma

被引:4
|
作者
Yang L. [1 ,2 ]
Bai Y. [1 ]
Han X. [1 ,2 ]
Shi Y. [3 ,4 ]
Liu H. [1 ]
机构
[1] Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Beijing National Laboratory for Molecular Sciences, Institute of Analytical Chemistry, College of Chemistry and Molecular Engineering, Peking University, Beijing
[2] Department of Pharmacy, Shanxi Medical University, Taiyuan
[3] Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
[4] Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing
基金
中国国家自然科学基金;
关键词
Biomarker; Hepatocellular carcinoma; Lipidomics; NP/RP 2D LC-QToF/MS;
D O I
10.1007/s41664-017-0028-2
中图分类号
学科分类号
摘要
Hepatocellular carcinoma (HCC) accounts for the major primary liver cancer, and its morbidity and mortality rates are very high. Identification of novel biomarkers for the early diagnosis and treatment of this disease is of crucial importance. In this study, a continuous-flow normal-phase/reversed-phase two-dimensional liquid chromatography—quadrupole time-of-flight mass spectrometry (NP/RP 2D LC-QToF/MS) method was used to detect lipid species in human plasma from HCC patients and healthy controls. As a result, the two groups were clearly separated by principal component analysis. Besides, 23 lipid species with corrected p value <0.05 and fold change >1.5 were proposed as potential lipid biomarkers for HCC. Among them, 9 lipid species, including galactosylceramide (36:5), free fatty acid (20:4), phosphatidylethanolamine (40:6), phosphatidylethanolamine (38:6), diacylglycerol (40:5), diacylglycerol (44:2), lactosylceramide (40:3), phosphatidylcholine (40:6), and free fatty acid (22:5), exhibited excellent ability to distinguish HCC patients from healthy controls with the area under the receiver-operating characteristic curve >0.900, showing promising clinical value. Taken together, these results indicate the great potential of NP/RP 2D LC-QToF/MS method in disease diagnosis, which might be helpful in clinical practice. © 2017, The Nonferrous Metals Society of China and Springer Nature Singapore Pte Ltd.
引用
收藏
页码:223 / 232
页数:9
相关论文
共 50 条
  • [1] Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
    Sanchez, Jessica, I
    Jiao, Jingjing
    Kwan, Suet-Ying
    Veillon, Lucas
    Warmoes, Marc O.
    Tan, Lin
    Odewole, Mobolaji
    Rich, Nicole E.
    Wei, Peng
    Lorenzi, Philip L.
    Singal, Amit G.
    Beretta, Laura
    CANCER PREVENTION RESEARCH, 2021, 14 (10) : 955 - 962
  • [2] Comparative proteomics analysis to identify biomarkers of hepatocellular carcinoma
    Cho, S. W.
    Cheong, J. Y.
    Na, Y. M.
    Lee, M. H.
    Kim, D. K.
    Paik, Y. K.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S142 - S142
  • [3] Comparative proteomics analysis to identify biomarkers of hepatocellular carcinoma
    Yeo, Marie
    Na, Young Mi
    Kim, Dong-Kyu
    Park, Hee Jin
    Lee, Kwang Jae
    Cho, Sung Won
    GASTROENTEROLOGY, 2008, 134 (04) : A466 - A466
  • [4] Novel biomarkers in hepatocellular carcinoma
    De Stefano, Felice
    Chacon, Eduardo
    Turcios, Lilia
    Marti, Francesc
    Gedaly, Roberto
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (11) : 1115 - 1123
  • [5] CROSS-SPECIES COMPREHENSIVE PROTEOMIC ANALYSIS OF HEPATOCELLULAR CARCINOMA (HCC) TO IDENTIFY PLASMA BIOMARKERS OF VASCULAR INVASION
    Krishnan, Maya
    Arjunan, Vinodhini
    Kothary, Nishita
    Felsher, Dean
    Dhanasekaran, Renumathy
    HEPATOLOGY, 2019, 70 : 74A - 74A
  • [6] Integrative plasma proteomics identifies novel diagnostic biomarkers in hepatocellular carcinoma
    Zhou, Shuang
    Abe, Yuichi
    Isomura, Hisanori
    Ishigami, Masatoshi
    Fujishiro, Mitsuhiro
    Taguchi, Ayumu
    CANCER SCIENCE, 2023, 114 : 58 - 58
  • [7] Integrative Analysis to Identify Race-Associated Metabolite Biomarkers for Hepatocellular Carcinoma
    Chen, Yifan
    Barefoot, Megan E.
    Varghese, Rency S.
    Wang, Kuijun
    Di Poto, Cristina
    Ressom, Habtom W.
    42ND ANNUAL INTERNATIONAL CONFERENCES OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY: ENABLING INNOVATIVE TECHNOLOGIES FOR GLOBAL HEALTHCARE EMBC'20, 2020, : 5300 - 5303
  • [8] Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
    Ao, Huang
    Xin, Zhang
    Jian, Zhou
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [9] Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
    Huang Ao
    Zhang Xin
    Zhou Jian
    Biomarker Research, 9
  • [10] Identification of novel biomarkers for hepatocellular carcinoma using transcriptome analysis
    Xia, Qianlin
    Li, Zehuan
    Zheng, Jianghua
    Zhang, Xu
    Di, Yang
    Ding, Jin
    Yu, Die
    Yan, Li
    Shen, Longqiang
    Yan, Dong
    Jia, Ning
    Chen, Weiping
    Feng, Yanling
    Wang, Jin
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (04) : 4851 - 4863